tbuckley/cabot-search huggingface dataset:
Phase I study of two different schedules of bortezomib (BORT) and pemetrexed (PEM) in advanced solid tumors
Authors: A. S. Metzger, P. Lara, D. Lau, P. Mack, P. Gumerlock, D. Gandara, A. M. Davies
Journal: Journal of Clinical Oncology (2006)

17051 Background: BORT(PS-341) is a small molecule proteasome inhibitor while PEM, a multi-targeted antifolate, inhibits multiple enzymes involved in purine/pyrimidine formation. Both are approved anti-cancer agents. We examined the safety and tolerability of two different schedules of BORT and PEM in patients with advanced solid tumors. Methods: Two dose escalation trials (Arm A and Arm B) were conducted simultaneously. PEM was given every 21 days in both arms (500–600 mg/m 2 IV). Arm A: BORT was given D1,4,8 &amp;11 (0.7–1.3 mg/m 2 ). Arm B: BORT was given D1 &amp; 8 (1.0–1.6 mg/m 2 ). All patients received vitamin B12, folic acid and decadron. Dose limiting toxicity (DLT) was defined as: grade (GR) 4 platelets (plts) (≤25K); GR 3 plts (25K-49,999K) with bleeding, requirement for transfusion, or lasting &gt; 7 days; febrile neutropenia; GR3 ANC (ANC ≤1.0 × 10 9 ) with documented infection, or any ≥ GR3 non-heme toxicity. Results: 18 patients have been treated on 3 of the 4 planned dose levels. Tumor types included lung (12), prostate (2), breast (1), thymus (1), head &amp; neck (1) and adenoid cystic carcinoma (1). Pt. characteristics: Median age 65 years; Sex M/F = 7/11; Performance Status ≤1/2 = 18/0. There have been no DLTs in either arm (Dose level 3-Arm A: PEM 500 mg/m 2 , BORT 1.3 mg/m 2 ; Arm B:PEM 500 mg/m 2 , BORT 1.6 mg/m 2 ). Most common GR3/4 toxicities were: neutropenia 27% and lymphopenia 11%. Of 17 evaluable patients: 1 had partial response, 11 had stable disease, 5 had progressive disease. Mean number of cycles: 4. Arm A had more doses held during the first cycle than Arm B (6 doses held vs. 1 dose held). Accrual to the final dose level in both arms is ongoing. Conclusions: 1) PEM in combination with BORT is feasible and tolerable. 2) Thus far, there are no differences in toxicity between the arms. 3) A randomized, multi-institutional phase II study will examine the efficacy of these two schedules in patients with NSCLC. No significant financial relationships to disclose.
Abstract 18483: Randomized, Double Blind Trial of Tapered versus Abrupt Interruption of Long Term Clopidogrel Therapy After Drug-Eluting Stent Implantation - ISAR-CAUTION
Authors: Kathrin A Fiedler, Julinda Mehilli, Sebastian Kufner, Nonlag Rifatov, Anna Schlichting, Heidrun Holle, Tareq Ibrahim, Karl-Ludwig Laugwitz, Adnan Kastrati, Stefanie Schulz
Journal: Circulation (2013)

Purpose: Observational data suggest clustering of thrombotic events after cessation of antithrombotic therapy in patients with coronary artery disease. The underlying mechanism has been ascribed to a potential rebound platelet activity after discontinuation of chronic clopidogrel therapy. This may have a negative impact particularly in patients receiving drug-eluting stents. We therefore hypothesized that gradual clopidogrel therapy cessation attenuates the potential risks associated with abrupt clopidogrel therapy cessation in that patient population. Methods: Patients with planned discontinuation of chronic clopidogrel therapy after drug-eluting stent implantation were randomized in a double-blinded fashion to either gradual or abrupt interruption of clopidogrel therapy. The primary endpoint is a composite of cardiac death, myocardial infarction, stroke, stent thrombosis (definite or probable), major bleeding or rehospitalisation due to an acute coronary syndrome at 3 months after randomization. The trial is registered with ClinicalTrials.gov Identifier: NCT00640679 . Results: Enrollment was stopped prematurely due to slow recruitment. A total of 782 patients were enrolled. Follow-up has been completed. Results will be available in June 2013. Conclusions: The results will help to define the best way of clopidogrel therapy cessation after drug-eluting stent implantation.
Acute-Onset Endophthalmitis after Clear Corneal Cataract Surgery (1996–2005)
Authors: Geeta A. Lalwani, Harry W. Flynn, Ingrid U. Scott, Carolyn M. Quinn, Audina M. Berrocal, Janet L. Davis, Timothy G. Murray, William E. Smiddy, Darlene Miller
Journal: Ophthalmology (2007)
Campaigners challenge patent applications for hepatitis C drug in five countries
Authors: S. Bagcchi
Journal: BMJ (2015)

Campaigning groups are challenging patent applications for the blockbuster hepatitis C drug sofosbuvir (Sovaldi) in Argentina, Brazil, China, Russia, and Ukraine to improve access to the drug.

I-MAK, a US based group that campaigns for increased access to affordable medicines, has claimed that Gilead Sciences, the US biotechnology company that makes Sovaldi, is seeking “illegitimate patents” for sofosbuvir and “blocking millions of people around the world from getting the treatment” for hepatitis C.1

The group alleged that the base compound in sofosbuvir is not new and is already covered by earlier patents. I-MAK, together with an Indian organisation, Delhi Network of Positive People, opposed the patent application for sofosbuvir in India on the grounds that no new evidence showed it to have enhanced efficacy over known forms of the compound. India’s patent office rejected the application for sofosbuvir in January on the grounds that sofosbuvir …
Cours d'hygiène.
Authors: G. Perrin, H. Coupin
Journal: JAMA (1928)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Cyclopedia of Medicine, Surgery, Specialties.
Authors: George Morris
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Electrical pharyngeal stimulation for dysphagia treatment in tracheotomized stroke patients: a randomized controlled trial
Authors: Sonja Suntrup, Thomas Marian, Jens Burchard Schröder, Inga Suttrup, Paul Muhle, Stephan Oelenberg, Christina Hamacher, Jens Minnerup, Tobias Warnecke, Rainer Dziewas
Journal: Intensive Care Medicine (2015)
Idiopathic basal ganglia calcification and organic mood disorder
Authors: R. J. Trautner, Jeffrey L Cummings, S. L. Read, D. F. Benson
Journal: American Journal of Psychiatry (1988)

Idiopathic basal ganglia calcification is a syndrome consisting of bilateral basal ganglia calcifications, neuropsychiatric abnormalities, disturbances of movement, and normal calcium and phosphorus metabolism. The best described neuropsychiatric alterations are dementia and an organic psychosis. Organic mood disorder has been reported less often, and mania secondary to idiopathic basal ganglia calcification has not been noted previously. The authors describe five patients with idiopathic basal ganglia calcification and organic mood changes, including one patient with secondary mania. Symptoms of idiopathic basal ganglia calcification resemble those of other disorders affecting subcortical structures and support an association between mood, affect, cognition, and the extrapyramidal nuclear system. Treatment may ameliorate the mood disorder.
Differences in clinical trial patient attributes and outcomes according to trial enrollment setting: analyses from 10 CALGB lung cancer trials
Authors: E. B. Lamont, L. E. Archer, L. Lan, E. E. Vokes, B. J. McNeil, N. L. Keating, M. Landrum
Journal: Journal of Clinical Oncology (2008)

6517 Background: Over the last 25 years, National Cancer Institute (NCI) cooperative trial groups have extended their trial networks from solely academic medical centers to include community and VA medical centers. Aims: We sought to determine (1) if there are differences in trial patient attributes (i.e., case-mix) according to type of enrollment setting (i.e., academic, community and VA) and (2) whether after adjusting for patient case-mix, there are differences in patients' trial outcomes attributable to enrollment setting. Methods: Studying 2,708 patients nested within 272 institutions who were enrolled on one of ten CALGB phase III lung cancer trials between the years 1990–2006, we evaluated trial patient (1) attributes and (2) survival outcomes according to enrollment setting. We defined enrollment setting as academic=main member, community=community affiliate, and VA=VA affiliate. Results: Overall, 44% of patients were enrolled at main member institutions, 44% at community affiliates, and 12% at VA affiliates. We found differences in prognostically important patient attributes by enrollment setting. For example, patients enrolled at main member sites were, on average, younger, more likely to be married and better-educated compared to patients enrolled at either community or VA affiliates. However, in two-level multivariable regression models that adjusted for these differences in patient case-mix across enrollment settings, we found no difference in patients' one year survival by setting. Conclusions: There are clinically important differences in trial patient case-mix across academic, community and VA enrollment settings which could lead to spurious survival differences by enrollment setting in unadjusted analyses. However after adjusting for patient case-mix, we find that enrollment setting itself did not effect patient survival. This suggests that the cancer care patients receive outside of academic centers may be equivalent to that of academic centers when it is delivered through an NCI cooperative group clinical trial. Further research is needed to evaluate this hypothesis among trial patients enrolled on complex multi-modality trials and trials for malignancies with longer survival horizons. No significant financial relationships to disclose.
Evaluation on the IGF-IR Inhibitor CP-751,871, alone and in combination with paclitaxel in lung and colon cell lines
Authors: R. Garcia-Carbonero, M. T. Agullo-Ortuño, F. Lopez-Rios, C. V. Diaz-Garcia, A. Cortijo, H. Cortes-Funes, L. Paz- Ares
Journal: Journal of Clinical Oncology (2009)

e22125 Background: Signaling through the insulin-like growth factor 1 receptor (IGF-IR) has been implicated in the resistance to a number of clinically relevant anti-cancer agents. The aim of this study was to assess the direct anti-tumour effects of CP-751,871, alone and in combination with paclitaxel in lung and colon cancer cell lines. Methods: Four lung and four colon cancer cell line where treated with the IGF-IR inhibitor CP-751,871 and/or Paclitaxel in simultaneous or sequential treatments. Response to treatments was evaluated by WST-1 cell survival assays. Flow cytometric analysis was used to estimate the effect on the cell cycle and apoptosis. IGF-IR mRNA expression was determined by quantitative real-time PCR and relative gene expression values were calculated by the ΔΔCt method. Results: No correlation between basal IGF-IR mRNA expression and CP-751,871 response was observed in cell lines tested. Flow cytometric analysis demonstrated that CP-751,871 enhanced cell cycle arrest at the G1/G0 checkpoint with minimal effects on apoptosis. Combined simultaneous and, more strongly, sequential treatment with CP- 751,871 and Paclitaxel showed improved response in cell growth inhibition on HCC78, H1299, Colo205 and HT29 cell lines, and was statistically superior to Paclitaxel alone (p&lt; 0.001) and CP-751,871 alone (p&lt; 0.001). In H460, LS180 and DLD-1 cell lines, concomitant, but no sequential treatment resulted in antagonistic interactions. Conclusions: CP-751,871 showed a modest anti-tumour activity, predominantly cytostatic, against lung and colon cancer cell lines, that is not related to the mRNA expression. CP-751,871 tends to enhance the effects of paclitaxel in vitro, depending on sequence of administration and on the model system used. No significant financial relationships to disclose.
A Textbook of Pharmacognosy.
Authors: N. M. Ferguson
Journal: Annals of Internal Medicine (1950)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 15338: Glycemic Variability Determined by a Continuous Glucose Monitoring System Predicts the Extent of the Peri-Infarct Zone and Left Ventricular Remodeling in Patients With a First-Time ST-Segment Elevation Myocardial Infarction.: Cardiac MRI study
Authors: Masaomi Gohbara, Noriaki Iwahashi, Shunsuke Kataoka, Kozo Okada, Masaaki Konishi, Nobuhiko Maejima, Kengo Tsukahara, Yoshio Tahara, Kiyoshi Hibi, Masami Kosuge, Toshiaki Ebina, Satoshi Umemura, Kazuo Kimura
Journal: Circulation (2013)
Occupational Lead Exposure and Associations with Selected Cancers: The Shanghai Men’s and Women’s Health Study Cohorts
Authors: Linda M. Liao, Melissa C. Friesen, Yong-Bing Xiang, Hui Cai, Dong-Hee Koh, Bu-Tian Ji, Gong Yang, Hong-Lan Li, Sarah J. Locke, Nathaniel Rothman, Wei Zheng, Yu-Tang Gao, Xiao-Ou Shu, Mark P. Purdue
Journal: Environmental Health Perspectives (2015)

BackgroundEpidemiologic studies of occupational lead exposure have suggested increased risks of cancers of the stomach, lung, kidney, brain, and meninges; however, the totality of the evidence is inconsistent.ObjectiveWe investigated the relationship between occupational lead exposure and cancer incidence at the five abovementioned sites in two prospective cohorts in Shanghai, China.MethodsAnnual job/industry-specific estimates of lead fume and lead dust exposure, derived from a statistical model combining expert lead intensity ratings with inspection measurements, were applied to the lifetime work histories of participants from the Shanghai Women's Health Study (SWHS; n = 73,363) and the Shanghai Men's Health Study (SMHS; n = 61,379) to estimate cumulative exposure to lead fume and lead dust. These metrics were then combined into an overall occupational lead exposure variable. Cohort-specific relative hazard rate ratios (RRs) and 95% confidence intervals (CIs) comparing exposed and unexposed participants were estimated using Cox proportional hazards regression and combined by meta-analysis.ResultsThe proportions of SWHS and SMHS participants with estimated occupational lead exposure were 8.9% and 6.9%, respectively. Lead exposure was positively associated with meningioma risk in women only (n = 38 unexposed and 9 exposed cases; RR = 2.4; 95% CI: 1.1, 5.0), particularly with above-median cumulative exposure (RR = 3.1; 95% CI: 1.3, 7.4). However, all 12 meningioma cases among men were classified as unexposed to lead. We also observed non-significant associations with lead exposure for cancers of the kidney (n = 157 unexposed and 17 ever exposed cases; RR = 1.4; 95% CI: 0.9, 2.3) and brain (n = 67 unexposed and 10 ever exposed cases; RR = 1.8; 95% CI: 0.7, 4.8) overall.ConclusionsOur findings, though limited by small numbers of cases, suggest that lead is associated with the risk of several cancers in women and men.CitationLiao LM, Friesen MC, Xiang YB, Cai H, Koh DH, Ji BT, Yang G, Li HL, Locke SJ, Rothman N, Zheng W, Gao YT, Shu XO, Purdue MP. 2016. Occupational lead exposure and associations with selected cancers: the Shanghai Men's and Women's Health Study cohorts. Environ Health Perspect 124:97–103; http://dx.doi.org/10.1289/ehp.1408171
Desmoid tumor of the stomach
Authors: Keiichi Date, Yasuo Shima, Takehiro Okabayashi, Jun Iwata, Tatsuaki Sumiyoshi, Akihito Kozuki
Journal: Endoscopy (2015)

A 56-year-old man was referred to our department for evaluation of a gastric mass. His medical history revealed that he had undergone distal gastrectomy for an early gastric carcinoma 18 months previously. Abdominal computed tomography (CT) demonstrated a well-defined, contrast-enhancing mass, 3.3 cm in diameter, with uniform inner structure in the stomach ([Fig. 1]). Esophagogastroduodenoscopy (EGD) showed a 3.0-cm, submucosal tumor in the greater curvature of the remnant stomach ([Fig. 2 a]). Endoscopic ultrasound (EUS) of this lesion showed it to be a hypoechoic mass with a sharp boundary in the fourth layer ([Fig. 2 b]).
Ability, A Psychological Study.
Authors: Victoria Hazlitt
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Ambassadors in White: The Story of American Tropical Medicine
Authors: Charles Morrow Wilson
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal